Format

Send to

Choose Destination
J Clin Invest. 2020 Feb 3;130(2):904-920. doi: 10.1172/JCI130767.

Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models.

Author information

1
Department of Psychiatry and.
2
Molecular Neurobiology Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
3
Department of Molecular and Life Sciences, Hanyang University, Ansan, Korea.
4
Department of Pediatrics.
5
Computational Health Informatics Program, Boston Children's Hospital, and.
6
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
7
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of striatal dopamine, secondary to degeneration of midbrain dopamine (mDA) neurons in the substantia nigra, rendering cell transplantation a promising therapeutic strategy. To establish human induced pluripotent stem cell-based (hiPSC-based) autologous cell therapy, we report a platform of core techniques for the production of mDA progenitors as a safe and effective therapeutic product. First, by combining metabolism-regulating microRNAs with reprogramming factors, we developed a method to more efficiently generate clinical-grade iPSCs, as evidenced by genomic integrity and unbiased pluripotent potential. Second, we established a "spotting"-based in vitro differentiation methodology to generate functional and healthy mDA cells in a scalable manner. Third, we developed a chemical method that safely eliminates undifferentiated cells from the final product. Dopaminergic cells thus express high levels of characteristic mDA markers, produce and secrete dopamine, and exhibit electrophysiological features typical of mDA cells. Transplantation of these cells into rodent models of PD robustly restores motor function and reinnervates host brain, while showing no evidence of tumor formation or redistribution of the implanted cells. We propose that this platform is suitable for the successful implementation of human personalized autologous cell therapy for PD.

KEYWORDS:

Neuroscience; Parkinson’s disease; Stem cell transplantation; Stem cells

PMID:
31714896
PMCID:
PMC6994130
[Available on 2020-05-03]
DOI:
10.1172/JCI130767
Free full text

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation
Loading ...
Support Center